About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 172 record(s)
Req # A-2022-001090
Adverse Drug Reaction (ADR). Report number: E2B_05211145.Organization: Health Canada
February 2023
Req # A-2022-001095
Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: E2B_01775951, E2B_01780967, E2B_02142492, E2B_02272688, E2B_02272700, 000715927, E2B_01738850, E2B_02094125.Organization: Health Canada
February 2023
Req # A-2022-001101
Adverse Drug Reactions (ADRs). Report numbers: E2B_05628351, E2B_05694473, E2B_05687302, E2B_05687063, 001005149, E2B_05612914, E2B_05712679, E2B_05628171, E2B_05702195, E2B_05671988.Organization: Health Canada
February 2023
Req # A-2022-001102
Adverse Drug Reaction (ADR). Report number: E2B_05793536.Organization: Health Canada
February 2023
Req # A-2022-001104
Adverse Drug Reactions (ADRs). Report numbers: E2B_05659134, E2B_05656745, E2B_05657666, E2B_05632301, E2B_05632251, E2B_05617673, E2B_05641260, E2B_05648553, E2B_05660790, 001004906.Organization: Health Canada
February 2023
Req # A-2022-001113
Adverse Drug Reaction (ADR). Report number: E2B_05622830.Organization: Health Canada
February 2023
Req # A-2022-001130
Adverse Drug Reaction (ADR). Report number: E2B_05731191.Organization: Health Canada
February 2023
Req # A-2022-001136
Adverse Drug Reactions (ADRs) for VEDOLIZUMAB. Report numbers: 1015096, E2B_05740658, E2B_05799010, E2B_05793452, E2B_05743132, E2B_05710173, E2B_05773254, E2B_05790450, E2B_05799925, E2B_05756619.Organization: Health Canada
February 2023
Req # A-2022-001140
Adverse Drug Reaction (ADR) for MEZAVANT. Report number: 001010016. ADRs for MESALAZINE. Report numbers: E2B_05749207, E2B_05793049, 001010704, 001010568, 001014435, 001010569, 001013512, 001015438. ADR for MESALAMINE. Report number: E2B_05759898.Organization: Health Canada
February 2023
Req # A-2022-001144
Adverse Drug Reactions (ADRs) for IMMUNOGLOBULIN (HUMAN). Report numbers: 001011026, 001010781, 001010789, 001011015, 001011409, 001011229. ADR for ICATIBANT (ICATIBANT ACETATE). Report number: E2B_05768233. ADRs for ANTIHEMOPHILIC FACTOR (HUMAN). Report numbers: E2B_05750435, E2B_05724550, E2B_05724546.Organization: Health Canada
February 2023